• The field of gene therapy is exploding with rapidly occurring advances, and there are virtually unlimited facilities for the future treatment of GBM. • Aptamers have unique features for use in the treatment of GBM and other malignant tumors. These features include high sensitivity and specificity for their target structure, low-cost and rapid manufacture, heat and dehydration resistance, low toxicity and immunostimulation, easy chemical modification, and an aptamer that can merely pass through the BBB, which can be considered as an ineffective treatment. • miRNAs have led to the identification of new therapeutic targets in many diseases and cancers. Therapeutic targets based on miRNAs in the early stages of the disease onset can hopefully be an effective step in the treatment of glioblastoma. • MSCs and NSCs have a similar tendency to glioma and therefore have a high carrier capacity. Understanding the properties that allow NSCs and MSCs to effectively migrate toward the tumor will be vital for gene therapy. The field of gene therapy is exploding with rapidly occurring advances, and there are virtually unlimited facilities for the future treatment of GBM. Aptamers have unique features for use in the treatment of GBM and other malignant tumors. These features include high sensitivity and specificity for their target structure, low-cost and rapid manufacture, heat and dehydration resistance, low toxicity and immunostimulation, easy chemical modification, and an aptamer that can merely pass through the BBB, which can be considered as an ineffective treatment. miRNAs have led to the identification of new therapeutic targets in many diseases and cancers. Therapeutic targets based on miRNAs in the early stages of the disease onset can hopefully be an effective step in the treatment of glioblastoma. MSCs and NSCs have a similar tendency to glioma and therefore have a high carrier capacity. Understanding the properties that allow NSCs and MSCs to effectively migrate toward the tumor will be vital for gene therapy. The most malignant tumor of the brain, with a low survival rate, is glioblastoma multiforme. Importantly, routine medical therapeutic techniques do not provide a stable and confident strategy for treatment and diagnosis. In this way, translational elements, including gene therapy, such as suicide gene therapy, tumor suppressor gene therapy, oncolytic virus therapy, nanoparticles, mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and aptamers as a new probe in detecting the target structure, are of great importance in GBM therapy. In this review article, we discussed the above elements as a new and practical approach to the diagnosis and treatment of GBM in detail.
Norollahi et al. (Sun,) studied this question.